Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Tessa GargettNga T H TruongBryan GardamWenbo YuLisa M EbertAmy JohnsonErica C F YeoNicole L WittwerGonzalo Tapia RicoJesikah LoganPurany SivaloganathanMaria CollisAndrew RuszkiewiczMichael P BrownPublished in: Journal for immunotherapy of cancer (2024)
ACTRN12613000198729.